Caribou Biosciences stock (US1420381089): Q1 earnings beat and 4.4% surge

Caribou Biosciences reported Q1 2026 earnings on May 7 with EPS of -$0.26 beating estimates by $0.07 and revenue of $2.4M topping forecasts. Shares gained 4.43% to $2.12 on May 13 on Nasdaq amid conference news.

Caribou Biosciences stock surged 4.43% on May 13, 2026, closing at $2.12 from $2.03 on Nasdaq, according to StockInvest.us as of May 13, 2026. This followed Q1 2026 earnings released May 7, where EPS of -$0.26 beat consensus estimates of -$0.33 by $0.07, and revenue hit $2.40 million versus expected $2.21 million, per MarketBeat as of May 7, 2026. The clinical-stage CRISPR firm also announced participation in the H.C. Wainwright BioConnect conference on May 19.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Caribou Biosciences, Inc.
• Sector/industry: Biotechnology / CRISPR genome editing
• Headquarters/country: Berkeley, California, USA
• Core markets: US, Europe (clinical trials)
• Key revenue drivers: Clinical milestones, collaborations
• Home exchange/listing venue: Nasdaq (CRBU)
• Trading currency: USD

Caribou Biosciences: core business model

Caribou Biosciences develops allogeneic CAR-T cell therapies using its proprietary CRISPR-based chRDNA platform for cancer and autoimmune diseases. The company, founded in 2011 and public since 2021, focuses on off-the-shelf treatments to improve accessibility over autologous therapies. Key programs include CB-010 for lupus and CB-011 for multiple myeloma, which received FDA RMAT designation on March 31, 2026, per the company's investor site as of March 31, 2026.

Revenue stems from collaboration agreements, grants, and clinical milestones rather than product sales, as all candidates remain in development. Q4 2025 results published March 5, 2026, highlighted pipeline progress without specific figures here. The model targets scalable manufacturing to address CAR-T manufacturing bottlenecks.

Main revenue and product drivers for Caribou Biosciences

Q1 2026 revenue of $2.40 million exceeded estimates, driven by milestone payments and grants during the period ended March 31, 2026, as reported May 7, per MarketBeat as of May 7, 2026. Lead candidate vispa-cel (CB-010) advances in Phase 1 for systemic lupus erythematosus, with updates slated for the 2026 EHA meeting. CB-011's RMAT status accelerates potential approval paths for relapsed/refractory multiple myeloma.

Pipeline expansion includes CB-010 in autoimmune indications and next-gen programs. Near-term catalysts involve data readouts and conferences like the May 19 H.C. Wainwright event, announced May 13 via Barchart as of May 13, 2026. Q2 earnings are estimated for August 12, with consensus revenue at $1.64 million.

Industry trends and competitive position

The CRISPR therapeutics sector grows with demand for precise gene editing in oncology and autoimmunity. Caribou competes with CRISPR Therapeutics and Editas Medicine but differentiates via chRDNA for higher fidelity edits. Allogeneic CAR-T reduces costs versus autologous leaders like Gilead's Yescarta, appealing to US payers amid $400K+ list prices.

Why Caribou Biosciences matters for US investors

Listed on Nasdaq, Caribou offers US investors exposure to gene editing innovation central to the $50B+ US biotech market. FDA designations like RMAT for CB-011 signal regulatory momentum, potentially unlocking US market access. Pipeline targets high-prevalence diseases like myeloma, aligning with US healthcare spending trends.

Conclusion

Caribou Biosciences demonstrated earnings resilience with a Q1 beat and share price momentum into May 2026. Pipeline milestones like RMAT and conference appearances underscore clinical progress in a competitive field. Investors track upcoming data and Q2 results for sustained trajectory amid biotech volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.